Lupin and pan-European pharmaceutical company Zentiva Group have entered into a license and supply agreement for commercialisation of Lupin’s biosimilar Certolizumab Pegol across multiple markets globally.
They will invest in the development of the biosimilar. Lupin will receive an initial payment of $10 million upon execution of the agreement and total development and regulatory milestone payments up to $50 million. The profits from the defined markets will be shared between the two companies, Lupin said in a release on Wednesday.
Lupin said it will be responsible for the development, manufacturing and supply of the product within the agreed territories. Zentiva will oversee commercialisation activities outside the U.S. and Canada, predominantly in Europe and CIS markets. Lupin will undertake commercialisation in remaining regions, including the U.S. and Canada.
Certolizumab Pegol is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis and Crohn’s disease, Lupin said.
Published – July 09, 2025 08:57 pm IST
